Form 4: BioXcel CFO Richard Steinhart Acquires Shares Through Equity Vesting

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, increased his direct ownership of common stock by 5,000 shares through the vesting of performance and restricted stock units.

Summary

• Richard Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc., acquired 5,000 shares of common stock on July 22, 2025.
• This acquisition includes 4,375 shares from the vesting of Performance Stock Units (PSUs) after the Compensation Committee determined performance conditions were satisfied.
• An additional 625 shares were acquired from the vesting of Restricted Stock Units (RSUs) granted on July 22, 2024, which vested 100% on their first anniversary.
• Following these transactions, Steinhart beneficially owns 6,441 shares of common stock directly.

Sentiment

Score: 7

Explanation: The filing indicates a routine vesting of equity awards for a key executive, which is a positive sign of management retention and alignment with shareholder interests, especially given the satisfaction of performance objectives for a portion of the awards. It does not, however, indicate new capital infusion or significant strategic shifts.

Positives

• Chief Financial Officer Richard Steinhart increased his direct ownership in the company by 5,000 shares, aligning his interests with shareholders.
• The vesting of 4,375 Performance Stock Units (PSUs) indicates that the Issuer's performance objectives were satisfied, as determined by the Compensation Committee.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and systematic acquisition of shares.

Industry Context

This filing reflects a routine equity compensation event for a senior executive in the biotechnology sector. Such vesting events are common mechanisms for aligning management incentives with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Financial Officer's interests with shareholders due to increased direct stock ownership.
• Employees: Reflects the company's commitment to executive compensation and retention through equity awards.

Key Dates

Recommendation

This Form 4 filing details the routine vesting of equity compensation for BioXcel Therapeutics' CFO, Richard Steinhart. While the increase in insider ownership is a positive signal of alignment, it does not represent a discretionary open-market purchase or a significant new development that would fundamentally alter the investment thesis. The transaction is an expected outcome of pre-existing compensation plans, thus warranting a 'hold' recommendation as it provides no new information to change an existing position.

Keywords

BioXcel Therapeutics, BTAI, Richard Steinhart, Chief Financial Officer, CFO, Insider Trading, Form 4, SEC Filing, Stock Acquisition, Restricted Stock Units, Performance Stock Units, Equity Compensation, Vesting